Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study.

Johnson P, Challis R, Chowdhury F, Gao Y, Harvey M, Geldart T, Kerr P, Chan C, Smith A, Steven N, Edwards C, Ashton-Key M, Hodges E, Tutt A, Ottensmeier C, Glennie M, Williams A.

Clin Cancer Res. 2015 Jan 14. [Epub ahead of print]

PMID:
25589626
[PubMed - as supplied by publisher]
2.

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015 Jan 14;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17.

PMID:
25341009
[PubMed - in process]
3.

The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.

Kiuchi T, Ortiz-Zapater E, Monypenny J, Matthews DR, Nguyen LK, Barbeau J, Coban O, Lawler K, Burford B, Rolfe DJ, de Rinaldis E, Dafou D, Simpson MA, Woodman N, Pinder S, Gillett CE, Devauges V, Poland SP, Fruhwirth G, Marra P, Boersma YL, Plückthun A, Gullick WJ, Yarden Y, Santis G, Winn M, Kholodenko BN, Martin-Fernandez ML, Parker P, Tutt A, Ameer-Beg SM, Ng T.

Sci Signal. 2014 Aug 19;7(339):ra78. doi: 10.1126/scisignal.2005157.

PMID:
25140053
[PubMed - in process]
4.

Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.

Watkins JA, Irshad S, Grigoriadis A, Tutt AN.

Breast Cancer Res. 2014 Jun 3;16(3):211. doi: 10.1186/bcr3670.

PMID:
25093514
[PubMed - in process]
Free PMC Article
5.

IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers.

Marra P, Mathew S, Grigoriadis A, Wu Y, Kyle-Cezar F, Watkins J, Rashid M, De Rinaldis E, Hessey S, Gazinska P, Hayday A, Tutt A.

Cancer Res. 2014 Sep 1;74(17):4908-21. doi: 10.1158/0008-5472.CAN-14-0637. Epub 2014 Jun 30.

PMID:
24980552
[PubMed - in process]
6.

Immunological visibility: posttranscriptional regulation of human NKG2D ligands by the EGF receptor pathway.

Vantourout P, Willcox C, Turner A, Swanson CM, Haque Y, Sobolev O, Grigoriadis A, Tutt A, Hayday A.

Sci Transl Med. 2014 Apr 9;6(231):231ra49. doi: 10.1126/scitranslmed.3007579.

PMID:
24718859
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Changes in primary breast cancer heterogeneity may augment midtreatment MR imaging assessment of response to neoadjuvant chemotherapy.

Parikh J, Selmi M, Charles-Edwards G, Glendenning J, Ganeshan B, Verma H, Mansi J, Harries M, Tutt A, Goh V.

Radiology. 2014 Jul;272(1):100-12. doi: 10.1148/radiol.14130569. Epub 2014 Mar 19.

PMID:
24654970
[PubMed - indexed for MEDLINE]
8.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.

Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.

PMID:
24519386
[PubMed - indexed for MEDLINE]
9.

Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

Eccles SA, Aboagye EO, Ali S, Anderson AS, Armes J, Berditchevski F, Blaydes JP, Brennan K, Brown NJ, Bryant HE, Bundred NJ, Burchell JM, Campbell AM, Carroll JS, Clarke RB, Coles CE, Cook GJ, Cox A, Curtin NJ, Dekker LV, Silva Idos S, Duffy SW, Easton DF, Eccles DM, Edwards DR, Edwards J, Evans D, Fenlon DF, Flanagan JM, Foster C, Gallagher WM, Garcia-Closas M, Gee JM, Gescher AJ, Goh V, Groves AM, Harvey AJ, Harvie M, Hennessy BT, Hiscox S, Holen I, Howell SJ, Howell A, Hubbard G, Hulbert-Williams N, Hunter MS, Jasani B, Jones LJ, Key TJ, Kirwan CC, Kong A, Kunkler IH, Langdon SP, Leach MO, Mann DJ, Marshall JF, Martin L, Martin SG, Macdougall JE, Miles DW, Miller WR, Morris JR, Moss SM, Mullan P, Natrajan R, O'Connor JP, O'Connor R, Palmieri C, Pharoah PD, Rakha EA, Reed E, Robinson SP, Sahai E, Saxton JM, Schmid P, Smalley MJ, Speirs V, Stein R, Stingl J, Streuli CH, Tutt AN, Velikova G, Walker RA, Watson CJ, Williams KJ, Young LS, Thompson AM.

Breast Cancer Res. 2013 Oct 1;15(5):R92. doi: 10.1186/bcr3493. Review.

PMID:
24286369
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk.

Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC.

Breast Cancer Res. 2013;15(5):R103.

PMID:
24172169
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A novel model of dormancy for bone metastatic breast cancer cells.

Marlow R, Honeth G, Lombardi S, Cariati M, Hessey S, Pipili A, Mariotti V, Buchupalli B, Foster K, Bonnet D, Grigoriadis A, Rameshwar P, Purushotham A, Tutt A, Dontu G.

Cancer Res. 2013 Dec 1;73(23):6886-99. doi: 10.1158/0008-5472.CAN-13-0991. Epub 2013 Oct 21.

PMID:
24145351
[PubMed - indexed for MEDLINE]
Free Article
12.

Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control.

de Rinaldis E, Gazinska P, Mera A, Modrusan Z, Fedorowicz GM, Burford B, Gillett C, Marra P, Grigoriadis A, Dornan D, Holmberg L, Pinder S, Tutt A.

BMC Genomics. 2013 Sep 23;14:643. doi: 10.1186/1471-2164-14-643.

PMID:
24059244
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.

Williams EL, Tutt AL, Beers SA, French RR, Chan CH, Cox KL, Roghanian A, Penfold CA, Butts CL, Boross P, Verbeek JS, Cragg MS, Glennie MJ.

J Immunol. 2013 Oct 15;191(8):4130-40. doi: 10.4049/jimmunol.1301430. Epub 2013 Sep 11.

PMID:
24026082
[PubMed - indexed for MEDLINE]
Free Article
14.

Agonist anti-human CD27 monoclonal antibody induces T cell activation and tumor immunity in human CD27-transgenic mice.

He LZ, Prostak N, Thomas LJ, Vitale L, Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A, Glennie MJ, Marsh H, Keler T.

J Immunol. 2013 Oct 15;191(8):4174-83. doi: 10.4049/jimmunol.1300409. Epub 2013 Sep 11.

PMID:
24026078
[PubMed - indexed for MEDLINE]
Free Article
15.

Signatures of mutational processes in human cancer.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN, Valdés-Mas R, van Buuren MM, van 't Veer L, Vincent-Salomon A, Waddell N, Yates LR; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR.

Nature. 2013 Aug 22;500(7463):415-21. doi: 10.1038/nature12477. Epub 2013 Aug 14. Erratum in: Nature. 2013 Oct 10;502(7470):258. Imielinsk, Marcin [corrected to Imielinski, Marcin].

PMID:
23945592
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Profiling the immune stromal interface in breast cancer and its potential for clinical impact.

Irshad S, Grigoriadis A, Lawler K, Ng T, Tutt A.

Breast Care (Basel). 2012 Aug;7(4):273-80. doi: 10.1159/000341529.

PMID:
23904829
[PubMed]
Free PMC Article
17.

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.

Gazinska P, Grigoriadis A, Brown JP, Millis RR, Mera A, Gillett CE, Holmberg LH, Tutt AN, Pinder SE.

Mod Pathol. 2013 Jul;26(7):955-66. doi: 10.1038/modpathol.2012.244. Epub 2013 Feb 8.

PMID:
23392436
[PubMed - indexed for MEDLINE]
Free Article
18.

Molecular characterisation of cell line models for triple-negative breast cancers.

Grigoriadis A, Mackay A, Noel E, Wu PJ, Natrajan R, Frankum J, Reis-Filho JS, Tutt A.

BMC Genomics. 2012 Nov 14;13:619. doi: 10.1186/1471-2164-13-619.

PMID:
23151021
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?

Turner NC, Tutt AN.

Breast Cancer Res. 2012 Nov 13;14(6):115. doi: 10.1186/bcr3332.

PMID:
23146216
[PubMed - in process]
Free PMC Article
20.

Differences in breast cancer hormone receptor status in ethnic groups: a London population.

Jack RH, Davies EA, Renshaw C, Tutt A, Grocock MJ, Coupland VH, Møller H.

Eur J Cancer. 2013 Feb;49(3):696-702. doi: 10.1016/j.ejca.2012.09.012. Epub 2012 Oct 8.

PMID:
23058788
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk